# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2024/20025116.pdf
Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(0.05) per share.